'Biohacker' reveals how life past 150 years will soon be 'inevitable' with data-driven health changes
Living 150 years could not just be possible – it could soon be inevitable, according to human biologist and biohacker Gary Brecka.
"If you're alive in five years, I believe it will be your choice whether or not you want to live to 120 to 150 years old," Brecka told Sean Hannity in a new installment of Fox Nation's "Sean" podcast.
"I truly believe that."
Brecka – a longevity expert who helps optimize human performance – joined Hannity for a no-holds-barred, hour-long discussion on what it takes to push past human limitations.
'Biohacker' Praises Maha Movement For 'Getting To The Root Causes' Of Health Issues
Modern bioscience, artificial intelligence and early detection are moving so quickly, he said, they're already paving the path toward massive life extension.
Read On The Fox News App
"Big data doesn't lie," he said.
"It has no agenda. Artificial intelligence can take voluminous amounts of data – 700 trillion independent variables – and create an actionable result."
What's coming, he predicted, is a future where A.I. and big data "circumvent" the system and people will be able to literally control their own fate, choosing how long – or short – they would like to live.
Living Longer, Not Healthier: Study Finds Longer Periods Of Poor Health Toward End Of Life
"It'll be your choice if you want to live 220, 250 [years]," he said ambitiously.
Brecka has worked with elite athletes and celebrities, including UFC President Dana White, helping them extend their healthspan and reverse concerning health issues through custom, data-driven protocols.
In White's case, Brecka says he multiplies his projected lifespan from just 10 years to nearly 40 by reversing metabolic syndrome – a cluster of conditions like hypertension, insulin resistance, high triglycerides, etc. that increase a person's risk for heart attack, stroke or Type 2 diabetes.
Click Here To Join Fox Nation
The transformation included a complete lifestyle overhaul: a diet change, red light therapy, breathing exercises, tailored exercise and ice water immersion helped White get his life back on track.
During the podcast, Brecka also revealed what he believes to be the most underrated key to longevity: connection.
To hear more about Brecka's transformative plan and the secrets to living a long, healthy life, subscribe to Fox Nation and stream the latest episode of the "Sean" podcast today.Original article source: 'Biohacker' reveals how life past 150 years will soon be 'inevitable' with data-driven health changes
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
President of the Association of American Physicians and Surgeons (AAPS) Writes, ‘Let's Make America Healthy Again'
TUCSON, Ariz., June 06, 2025 (GLOBE NEWSWIRE) -- The Make America Healthy Again (MAHA) project is a monumental task, writes Erika L. LeBaron, DO., M.S.N., in the summer issue of the Journal of American Physicians and Surgeons. Dr. LeBaron, current president of the Association of American Physicians and Surgeons (AAPS), practices family medicine with an osteopathic and integrative approach in Manassas, Va. The role of food and medicine must be addressed as a start. Factory-made foods look and taste good, but health and nutrition are not their focus, she states. In contrast to allopathic medicine, she explains, osteopathic medicine does not primarily emphasize medications and surgery, but rather the interconnectedness of body, mind, and spirit. Disease is seen as the body being at dis-ease vs. at ease or in balance. In the late19th century, allopathic medicine accepted the concept of monomorphism, that a particular germ creates a specific disease, as taught by Louis Pasteur and Robert Koch. However, two of their contemporaries believed that the inner condition of the body was more important than the germ itself. Antoine Bechamp formulated the pleomorphism theory, which held that germs have many forms and theorized that disease is a condition of one's internal environment (terrain), Dr. LeBaron writes. When her patients ask about vaccines, she discusses the germ theory vs. terrain theory. Vaccines are not the answer to health. She points to data from a pediatric practice showing that patients who were unvaccinated or had fewer vaccines were healthier in the long run than those patients who had more vaccinations. For treating disease, pharmaceuticals are not the only option, she writes, citing examples of physicians who successfully treated COVID patients without drugs. The key lesson, she writes, is that 'every patient is unique, and we must treat the patient not the disease. We must take a root-cause analysis and whole person approach to care, not a pharma/industry guideline or protocol.' The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS), a national organization representing physicians in all specialties since 1943. Contact: Jane M. Orient, M.D., (520) 323-3110, janeorientmd@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha Radhakrishnan, M.D., to the Company's Board of Directors (Board) effective June 4, 2025. 'We are delighted to welcome Maha as a new member of Candel's Board,' said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. 'Her extensive industry experience will be extremely valuable as Candel advances its late-stage oncology programs toward potential approval and commercial development, with the aim of providing benefit to patients with significant unmet need.' Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) submission for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026. "I am honored to join the Board at this pivotal moment as Candel advances its innovative immunotherapy candidates across multiple cancer indications," said Dr. Radhakrishnan. 'Candel's multimodal approach has the potential to address significant unmet needs in cancers that have historically been difficult to treat with conventional immunotherapies.' Dr. Radhakrishnan has over 20 years of experience advancing large strategic portfolios across various therapeutic areas through product development and commercialization within major biotechnology and pharmaceutical companies. Since August 2024, Dr. Radhakrishnan has served as an Executive Partner at Sofinnova Investments, a venture capital firm focused on life sciences, where she leads diligence across clinical-ready assets in multiple therapeutic areas and provides expertise to portfolio companies in product development and commercialization. Previously, Dr. Radhakrishnan served as Group Senior Vice President and Chief Medical Officer at Biogen Inc. Earlier in her career, she was Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi S.A. Dr. Radhakrishnan has also held leadership roles at Bioverativ, Inc., Bristol-Myers Squibb Company, UnitedHealth Group, Inc., and Cephalon, Inc. She received her M.D. with honors from the People's Friendship University in Moscow, Russia. 'Maha's expertise will be invaluable as we look forward to her contributions while we prepare to submit our Biologics License Application for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026,' said Paul B. Manning, Chairman of Candel's Board. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the submission of the Biologics License Application for CAN-2409 in intermediate-to-high-risk localized prostate cancer; and expectations regarding the therapeutic benefit of the Company's platforms. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact:Theodore JenkinsVP, Investor Relations and Business DevelopmentCandel Therapeutics, Media Contact:Ben ShannonICR HealthcareCandelPR@
Black America Web
10 hours ago
- Black America Web
Op-Ed: Care For Constituents Or Chaos? Medicaid Cuts Will Devastate All Of Us
Source: Jemal Countess / Getty In our country, which has so much abundance, poverty shouldn't be a death sentence. However, proposed cuts to Medicaid will cause many individuals, families and communities to suffer for that very reason–poverty. Significant and potentially massive cuts to Medicaid will cause irreparable harm. Shockwaves will reverberate in rural, urban, and suburban communities, and impact individuals, working families, many of our most fragile elderly and our most vulnerable young and disabled. I offer this perspective as a public health practitioner. I have spent my career supporting and advancing health systems in our country, across Louisiana, the Gulf Coast, and in our nation's capital, Washington, D.C., Medicaid supports our workforce and health systems (hospitals and clinics), in addition to individuals, families, and communities Medicaid provides insurance to people with low incomes and people who have disabilities. This includes many individuals who work, but still don't work jobs with health insurance, work part-time, or don't make enough to cover insurance. It is the nation's single largest health insurance program. And it is wildly popular. More than 96% of Americans believe the program is important in their communities and recent national polls from January 2025 found that 80% of Americans have a favorable view of Medicaid. Some may wonder if I am overreacting. I'm not. More than 70 million Americans receive health care coverage under the Medicaid program. In Louisiana, where I live, one-third of our adult population is on Medicaid, and the percentage of coverage is even higher in rural areas. In fact, Medicaid plays a much larger role in covering rural communities in Louisiana and across our country than it does in metro/areas. In other parts of the South, like rural Kentucky, more than 40% of the population is on Medicaid. These individuals, like all of us, want nothing more than to live healthy and thriving lives while making ends meet for their families and making their children's futures more prosperous. The public may envision people on Medicaid as unworthy of receiving assistance. But there is no one profile of a Medicaid recipient. They come from all backgrounds, all races and ethnicities, all ages and all communities. In fact, most low-income Americans, whether rural or urban, Black or White, Republican or Democrat, share an economic fate impacted by hardship, and the solution to their support and prosperity is also shared. For instance, 'The number of people earning less than $25,750 for a family of four is rising in both Republican and Democratic districts, and across racial and geographic lines.' It's also important to understand the range of services people receive from Medicaid. Services include everything from general health services, to behavioral health (mental health and substance use) services, disability services, maternal health supports and more. Impacts across all of these areas could be devastating with federal and state cuts to beneficiaries or benefits. For example, maternal health outcomes, particularly maternal mortality, continue to devastate families and communities across our country. Louisiana had the nation's fourth-highest maternal mortality rate in 2021 at 60.9 deaths per 100,000 births, but I know this is not just a Louisiana problem; it's a national one. The March of Dimes reported that '870 maternal deaths occurred each year…and every year 50,000 women experience a life-threatening complication (sometimes called a near-miss)' or severe maternal health complication. With such high risk, good coverage and high-quality care is more important than ever, and over 42% of all births in our country are covered by Medicaid. Reducing these Medicaid benefits would be disastrous to mothers, babies and families. Chancing the lives of mothers and babies is simply too risky! While I referenced maternal health, Medicaid supports the existence of healthier communities. Beyond the immediacy of illness, sick people can't work, study, or play. They can't contribute to their families, our communities, and the country's economy—from kids, to employers, to the GDP, everyone loses. Our nation's health systems, from rural health centers to large urban hospital systems receive critical funding to cover the millions of peoples seeking care. The healthcare sector, one of the most important sectors of our economy overall, relies heavily on Medicaid reimbursement to sustain jobs and services. Cuts of great magnitude will threaten clinics, hospitals and medical providers. We will see the impacts of this immediately in rural regions with the shuttering of services, significant job losses, and further diminishing already challenged access to care. With health care shortages already existing, our conversations need to be continued around closing the gaps in access, not creating new chasms. Now more than ever, we need our leaders and legislative champions to protect our communities and their health and well-being! Given the adverse impact Medicaid cuts would have on the nation, we need to boldly reject proposals that will weaken the program and impact all of our communities. Given its importance, some may wonder why elected leaders would want to cut the program. Some legislators propose cutting Medicaid as part of a broader plan to give $4.5 trillion in tax cuts. Others want to lower the federal deficit, a $1.1 trillion deficit at the end of February 2025. Policymakers should not attempt to bring down federal spending with ill-conceived strategies that will only add to Americans' suffering. They should instead think strategically about taxation. Legislators can bring a great deal of confidence in their leadership by examining other alternatives to drastic Medicaid cuts, by reminding us that they care for all of their constituents, and that they are creating a vision for a healthier future based on their community's needs—timely doctors' visits, healthy births, high quality mental health care and substance use supports—not disregarding, or even worse targeting the thing that keeps us safe and well. Shelina Davis is the Chief Executive Officer of the Louisiana Public Health Institute. SEE ALSO: 'We All Are Going To Die': Joni Ernst's Chilling Defense Of Medicaid Cuts Sparks Outrage At Iowa Town Hall The Midnight Medicaid Cuts: Why The GOP's Reconciliation Bill Is A Raw Deal For The American People SEE ALSO Op-Ed: Care For Constituents Or Chaos? Medicaid Cuts Will Devastate All Of Us was originally published on Black America Web Featured Video CLOSE
